Cannabidiol Reduces Signs of Multiple Sclerosis in Mouse Study

Non-psychoactive cannabinoid (CBD) reduced the clinical signs of multiple sclerosis (MS) and delayed disease onset in an experimental autoimmune encephalomyelitis (EAE) mouse model, according to a new study published in Frontiers in Immunology.

Marijuana CBD has been reported to exhibit anti-inflammatory and neuroprotective effects, demonstrating a potential therapeutic benefit for individuals with autoimmune diseases, including MS. However, the mechanisms through which CBD affects neuroinflammation are unclear.

In the study, the researchers sought to identify the mechanisms through which CBD suppresses neuroinflammation in MS-like disease by evaluating the effects of treatment with CBD on EAE mice.

Read The Rest of This Article Here!

Leave a Reply

Your email address will not be published. Required fields are marked *